Study of Ajovy in migraine published in Neurology journal.- Teva Pharma
Teva Pharmaceutical Industries announced that results from the 52-week, multicenter, randomized, double-blind, parallel group study evaluating monthly or quarterly Ajovy (fremanezumab-vfrm) injection in adults with chronic migraine (CM) or episodic migraine (EM), were published online ahead of print in Neurology.